4-碘-2,3-二氟甲苯 | 914100-41-7

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟甲苯系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-碘-2,3-二氟甲苯
• 英文名称: 2,3-Difluoro-1-iodo-4-methylbenzene
• CAS: 914100-41-7
• 化学式: C₇H₅F₂I
• 分子量: 254.02
• InChiKey: QKRIGLBQQDSLLN-UHFFFAOYSA-N

物化性质

• 密度：
  1.865

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] MANUFACTURE OF LACTO-N-TETRAOSE<br/>[FR] FABRICATION DE LACTO-N-TÉTRAOSE
  申请人：GLYCOM AS

  公开号：WO2012155916A1

  公开（公告）日：2012-11-22

  The present invention relates to the synthesis of the tetrasaccharide of formula (I) and novel intermediates used in the synthesis.

  本发明涉及公式（I）的四糖的合成以及合成中使用的新型中间体。
• [EN] A METHOD FOR OBTAINING CRYSTALLINE LACTO-N-TETRAOSE AND LACTO-N-NEOTETRAOSE PRECURSORS AND MIXTURES THEREOF<br/>[FR] PROCÉDÉ POUR OBTENIR DES PRÉCURSEURS DE LACTO-N-TÉTRAOSE ET DE LACTO-N-NEOTÉTRAOSE CRISTALLIN ET DES MÉLANGES DE CEUX-CI
  申请人：GLYCOM AS

  公开号：WO2013091660A1

  公开（公告）日：2013-06-27

  A mixture of, preferably a mixture consisting essentially of, an lacto-N-tetraose (LNT) precursor (1) and an lacto-N-neotetraose (LNnT) precursor (2), (formula 1, 2), where R is a group removable by hydrogenolysis and R3 is either a group removable by hydrogenolysis or H, a method of crystallizing 1 and/or 2 from said mixture, and the use of said mixture for making a mixture consisting essentially of LNnT and LNT for use as a pharmaceutically or nutritionally active ingredient. The precursors can be made by reacting an acceptor of formula 5, (formula 5), wherein R is a group removable by hydrogenolysis, R1 is acyl, Ri is acyl or H, R3 is selected from a group removable by hydrogenolysis, acyl, silyl and an acetal type group and Y is selected from alkanoylamido, haloalkanoylamido, -NAc2, benzamido, alkoxycarbonylamino, haloalkoxycarbonylamino, benzyloxycarbonylamino, azido, phthalimido, tetrachlorophthalimido, 2,3- diphenylmaleimido and 2,3-dimethylmaleimido, with a donor of formula 6, (formula 6), wherein R4 is acyl and Xi is selected from halogen, -OC(=NH)CCl3, -OAc, -OBz or -SR5, wherein R5 is selected from alkyl, substituted phenyl and unsubstituted phenyl, followed by one or more deprotection steps.

  一种混合物，优选基本上由乳糖-N-四糖（LNT）前体（1）和乳糖-N-新四糖（LNnT）前体（2）（式1，2）组成，其中R是通过氢解可移除的基团，R3是可通过氢解移除的基团或H，从该混合物中结晶1和/或2的方法，以及该混合物用于制备基本上由LNnT和LNT组成的混合物，作为药用或营养活性成分的用途。这些前体可以通过反应一个受体式5（式5），其中R是通过氢解可移除的基团，R1是酰基，Ri是酰基或H，R3是从可通过氢解移除的基团、酰基、硅基和缩醛型基团中选择的，Y是从烷酰胺基、卤代烷酰胺基、-NAc2、苯甲酰胺基、烷氧羰基氨基、卤代烷氧羰基氨基、苄氧羰基氨基、叠氮基、邻苯二甲酰亚胺基、四氯邻苯二甲酰亚胺基、2,3-二苯基马来酰亚胺基和2,3-二甲基马来酰亚胺基中选择的，与一个供体式6（式6）反应，其中R4是酰基，Xi是从卤素、-OC(=NH)CCl3、-OAc、-OBz或-SR5中选择的，其中R5是从烷基、取代的苯基和未取代的苯基中选择的，随后进行一个或多个脱保护步骤来制备。
• Liquid crystal carbonate and liquid crystal medium containing the same with positive or negative dielectric anisotropy
  申请人：Dabrowski Roman Slawomir

  公开号：US20130020532A1

  公开（公告）日：2013-01-24

  A novel liquid crystalline carbonate and the mixture containing the same: wherein R3 is an alkyl (H 2n+1 C n ) or an alkenyl (H 2n−1 C n ) group, each of 1 to 12 carbon atoms, the ring A is laterally unsubstituted benzene or pyridine or pyrimidine or trans-substituted cyclohexane ring, symbol r is 0 to 2; the lateral substituents: X 2 , X 3 , X 4 and X 5 in the benzene rings represent independently hydrogen or fluorine or chlorine atoms, X 1 is hydrogen or fluorine atom and simultaneously at least one of the substituents: X 2 , X 3 and X 4 is fluorine or chlorine atoms, Y is an alkyl or an alkyloxy or an alkenyl or an aikenyloxy group, each of 1 to 12 carbon atoms or hydrogen or fluorine or chlorine atom or NCS group are described.

  一种新型液晶碳酸酯及其含有的混合物：其中R3是一个烷基（H2n+1Cn）或烯基（H2n−1Cn）基团，每个基团含有1至12个碳原子，环A是侧链未取代的苯或吡啶或嘧啶或反取代的环己烷环，符号r为0至2；苯环中的侧链取代物X2、X3、X4和X5分别代表氢或氟或氯原子，X1为氢或氟原子，同时至少有一个取代物X2、X3和X4为氟或氯原子，Y是一个烷基或烷氧基或烯基或烯氧基基团，每个基团含有1至12个碳原子或氢或氟或氯原子或NCS基团。
• [EN] ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4<br/>[FR] ANTAGONISTES DU RÉCEPTEUR MUSCARINIQUE DE L'ACÉTYLCHOLINE M4
  申请人：UNIV VANDERBILT

  公开号：WO2019079783A1

  公开（公告）日：2019-04-25

  Disclosed herein are substituted hexahydro-lH-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

  本文披露了替代的六氢-1H-环戊[c]吡咯化合物，可能作为毒蕈碱乙酰胆碱受体M4（mAChR M4）的拮抗剂。本文还披露了制备这些化合物的方法、包含这些化合物的药物组合物、以及使用这些化合物和组合物治疗疾病的方法。
• [EN] SYNTHESIS OF THE TRISACCHARIDE 3-O-FUCOSYLLACTOSE AND INTERMEDIATES THEREOF<br/>[FR] SYNTHÈSE DE TRISACCHARIDE DE TYPE 3-O-FUCOSYLLACTOSE ET DE SES INTERMÉDIAIRES
  申请人：GLYCOM AS

  公开号：WO2013139344A1

  公开（公告）日：2013-09-26

  3-O-Fucosyllactose is made by process which includes the hydrogenolysis of a new compound of the formula 1 wherein R1 and R2 are independently a group removable by hydrogenolysis, and R3 is a group removable by hydrogenolysis or H; or a hydrate or solvate thereof.

  3-O-富醣乳醣是通過包括對式1中的新化合物進行氫解的過程製備的，其中R1和R2獨立地是可通過氫解去除的基團，R3是可通過氫解或H去除的基團；或其水合物或溶劑合物。